Investigation of Germline Genetic Determinants and Early Biomarkers of Cisplatin-Related Nephrotoxicity
This study will look for novel biomarkers of kidney injury in patients receiving cisplatin
in patients currently receiving cisplatin.
DNA will be collected both prospectively and retrospectively (from patients that have
previously received cisplatin.
Prospective Analysis Group
Observational Model: Case-Only, Time Perspective: Prospective
Change in urine biomarker (NGAL) after cisplatin
while on drug and up to 35 days after end of treatment
Peter H O'Donnell, MD
University of Chicago
United States: Institutional Review Board
|University of Chicago||Chicago, Illinois 60637|